London. In a significant development, the first complete results of an interim analysis have confirmed that the Oxford Kovid-19 vaccine is highly effective. Only three out of 23,745 participants have encountered severe adverse conditions during the vaccine trial. Interim results from the Oxford Covid-19 vaccine trials found that the vaccine protects against symptomatic disease in 70 percent of cases. 62 percent of vaccines were effective on those given two full doses and 90 percent on those given half.
The results are the first fully reviewed efficacy results to be published for the COVID-19 vaccine and have been published in The Lancet Magazine.
The result is based on a pre-specified pooled analysis of Phase 3 trials in the UK and Brazil (11,636 people), with a total of 23,745 people participating and safety data in 4 trials in the UK, Brazil and South Africa.
All participants have recovered or are recovering, and remain on trial.
“The results presented in this report provide important findings from our first interim analysis,” said study author and doctor Maryann Voysey of Oxford University.
He added that with more data in future analyzes, we will examine differences in major subgroups such as age, adults, people of different races, doses, timing of booster vaccines, and we will determine which immune responses to infection. Or better for protection from disease. “
The study noted that previous test results found that the vaccine elicited antibody and T cell immune responses, and is safe in adults 18 and older, including older adults.
The study’s lead author Professor Andrew Pollard said, “Our findings suggest that the efficacy of our vaccine exceeds the limits set by health authorities.”
Serious illness and hospitalization were monitored in all 23,745 participants. There were 10 cases reported for Kovid-19 since 21 days after the first dose, all under control, and two were severely categorized, including one death. (IANS)
read this also – Click to read the news of your state / city before the newspaper